Tina M. Neade
Chronic kidney disease, Glomerular disease, End stage renal disease, Kidney stones and Hypertension
Tina Neade, M.D., is an Assistant Professor of Medicine in the Division of Nephrology at Montefiore Medical Center/ Albert Einstein College of Medicine. She earned her medical degree at Albert Einstein College of Medicine, New York in 2002. She then completed her internal medicine residency at Mount Sinai Hospital in New York in 2005, followed by a nephrology fellowship at Mount Sinai Hospital in 2008. Dr Neade joined the faculty at Montefiore Medical Center in 2017. Dr. Neade is board certified in Internal Medicine and Nephrology.
Paul A. Levy
<p>Paul Levy, MD, is Director, Center for Inherited Metabolic Disorders and Director, Inherited Metabolic Disease Specialty Care Referral Center at the Children’s Hospital at Montefiore Einstein. He is also Associate Professor, Pediatrics and Pathology at our Albert Einstein College of Medicine. Dr. Levy sees patients with complex medical issues that may have a genetic etiology. He has a special interest in inherited metabolic disorders, including phenylketonuria (PKU), lysosomal storage diseases and urea cycle disorders, and sees newborns referred by the New York State Newborn Screening Program with positive screens.
</p><p>After earning his Doctor of Medicine at Tulane University, Dr. Levy completed his residency in pediatrics at Montefiore Einstein. He then completed a fellowship in ambulatory pediatrics at the same institution. Following this, Dr. Levy completed a fellowship in clinical and biochemical genetics at Tulane University. </p><p>Dr. Levy is involved in a long-term follow-up study for children with disorders diagnosed by newborn screening. He also participates in a study looking into a novel way to look at newborn screening and follow-up testing to determine if some infants with positive newborn screens may have a late-onset disease such as Pompe, Krabbe, and mucopolysaccharidosis (MPS I). Dr. Levy is on an advisory panel for Krabbe disease that helps physicians interpret clinical data to help determine infants’ status and help with needed follow-up. He has been principal investigator and co-investigator on clinical trials and funded research projects, and his work has been published in numerous peer-reviewed journals, review articles, book chapters and meeting abstracts. Dr. Levy has also given several nationally invited presentations and has been a journal reviewer for <em>Pediatrics Journal of Pediatrics and Genetics in Medicine</em>. </p><p>Dr. Levy is a Diplomat of the National Board of Medical Examiners and is board certified by the American Board of Pediatrics and the American Board of Medical Genetics. He is a member of many professional organizations, including the American Academy of Pediatrics, the American Society of Human Genetics, Society for Inherited Metabolic Disorders and the American College of Medical Genetics and Genomics. In 2023, Dr. Levy received the “Clinician Champion Award in Newborn Screening” from the Association of Public Health Laboratories.
</p>
Frederick J. Kaskel
<p>Frederick J. Kaskel, M.D., Ph.D., is an internationally recognized clinical investigator and educator in pediatric nephrology. He is a Chief Emeritus, Nephrology Children's Hospital at Montefioire, Albert Einstein College of Medicine. He is a Past President of the American Society of Pediatric Nephrology and the Congress President of the 15th Scientific Congress of the International Pediatric Nephrology Association.</p>
<p>He received his undergraduate bachelor's degree in Biology from Monmouth College, Monmouth, Ill., and his doctorate in Physiology and Medical Degree from the University of Cincinnati College of Medicine and is a Distinguished Alumnus from both of these institutions. He trained in Pediatrics and Pediatric Nephrology at Montefiore Medical Center and Albert Einstein College of Medicine, respectively and was a recipient of an NIH National Research Service Award. Prior to returning to Montefiore Medical Center and the Albert Einstein College of Medicine in 1998 to become the Director of Pediatric Nephrology, he was a tenured Professor of Pediatrics at the State University of New York at Stony Brook.</p>
<p>Dr. Kaskel's research interests range from basic science contributions in developmental renal physiology and mechanisms of renal toxicity and hypertension, to clinical and translational research in the etiologies and treatment of progressive kidney diseases secondary to nephrotic sydnrome and focal segmental glomerulosclerosis and hypertension. His current research is aimed at preventing the epidemic of obesity and cardiovascular risk factors and hypertension. He has received continuous research support from the National Institutes of Health and directs the Training Program in Pediatric Nephrology which prepares new physician investigators for careers in Pediatric Nephrology.</p>
<p>He published over 100 peer-reviewed articles, book chapters, and co-edited a major textbook on Fluids and Electrolytes in Pediatrics. He has numerous collaborations nationally and internationally and is expanding the communications between pediatric nephrology basic and clinical investigators worldwide. He currently plays a major role representing the Department of Pediatrics in the Einstein's prestigious Clinical Translational Science Award.</p>
Kidney disorders in infants, children and adolescents; end-stage kidney replacement therapy and transplantation
Prevention of kidney disease progression; prevention of hypertension and cardiovascular disease
<div class="WordSection1">
<ol start="1">
<li>Chandra M, Stokes MB, Kaskel FJ. Multinucleated podocytes: a diagnostic clue to cystinosis. Kidney Int. 2010 Nov;78(10):1052. PMID 21030980</li>
<li>Greenbaum LA, Munoz A, Schneider MF, kaskel FJ, Askenazi DJ, Jenkins R, Hotchkiss H, Moxey-Mims M, Furth SL, Warady BA. The association between abnormal birth history and growth in children with CKD. Clin J Am Soc Nephrol 011 Jan;6(1):14-21. PMC3022235</li>
<li>Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middelton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int. 2011 Mar;79(6):678-85. PMC3306823</li>
<li>Goilav B, Kaskel FJ. Chronic kidney disease stages are appropriate at all ages. Blood Purif. 2011;31(1-3):125- 129. PMID 21228580</li>
<li>Thomas R, Sanna-Cherchi S, Warady BA, Furth SL, Kaskel FJ, Gharavi AG. HNF1B and PAX2 mutations are a common cause of renal hypodysplasia in the CKiD cohort. Pediatr Nephrol. 2011 Jun;26(6):897-903. PMC3257470</li>
</ol>
</div>
<div class="WordSection2">
<ol start="6">
<li>Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMagan JL, Siegel N, D’Agati VD, Friedman AL. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011 Oct;80(8):868-78. PMC3306824</li>
<li>Furth SL, Abraham AG, Jerry-Fluker J, Schwartz GJ, Benfield M, Kaskel F, Wong C, Mak RH, Moxey-Mims M, Warady BA. Clin J Am Soc Nephrol. 2011 Sep;6(9):2132-40. PMC3358991</li>
<li>Gipson DS, Trachtman H, KaskelFJ, RadevaM, GassmanJ, GreeneT, Moxey-Mims M, HoggR, WatkinsS, FineR, MiddletonJ, VehaskariVM, HoganHL, VentoS, FlynnP, PowellL, McMahanJ, SiegelN, FriedmanA. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int. 2011 Mar; 79(6):678-85. PMC33068223</li>
<li>Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Surevey (NHANES):2001-2006. J Clin Endocrinol Metab. 2011 Sep28. PMC3232615</li>
<li>D’Agati V.D., Kaskel, FJ, and Falk RJ. Medical Progress: Focal Segmental Glomerulosclerosis. New England Journal of Medicine 2011 Dec: 365(25):2398-411. PMID 22187987</li>
<li>Wei C, Trachtman H, Li J, Dong, C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anaret A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel, F, Fischer DC, Schaefer F, Reiser, J. Circulating suPAR in two cohorts of primary FSGS. Clin J Am Soc Nephrol. 23:, 2012.</li>
<li>D’Agati VD, Alser JC, Jennette C, Thomas D, Pullman J, Savino D, Cohen A, Gipson D, Gassman J, Radeva M, Moxey-Mims M, Friedman A, Kaskel F, Trachtman H, Alpers C, Fogo A, Nast C. Histologic Variants in FSGS Clinical Trial biopsies correlate with outcome independent of remission status. Clin J Am Soc Nephrol. 2013; Mar;8(3):399-406. PMID: 23220425</li>
<li>Hogg R, Friedman A, Greene T, Radeva M, Budisavljevic M, Gassman J, Gipson D, Jefferson A, John E, Kaskel F, Moudgil A, Moxe-Mims M, Ortiz L, Schelling J, Schnaper H, Srivastava T, Trachtman H, Vehaskari V, Wong C, Worinicki R, Van Wy S, Zolotnitskaya A. Renal function and proteinuria after successful immunosuppressive therapies in patients with focal segmental glomerulosclerosis (FSGS). Clin J Am Soc Nephrol. 2013 Feb;8(2):211-8. PMID: 23143503</li>
<li>Ferris M, Norwood V, Radeva M, Gassman J, Amira A, Askenazi D, Mato T, Pinsk M, Sharma A, Smoyer W, Stults J, Vyas S, Weiss R, Gipson D, Kaskel F, Friedman A, Moxey-Mins M, Trachtman H. Patient recruitment in a multicenter randomized clinical trial for kidney disease: report of the Focal Segmental Glomerulosclerosis Clinical Trial. Clin Trans Sci 2013 Feb;6(1):13-20. PMID: 23399084</li>
<li>Gadegbeku C, Gipson D, Holzman L, Ojo A, Song P, Barisoni L, Sampson M, Kopp J, Lemley K, Nelson P, Lienczewski C, Adler S, Appel G, Cattran D, Choi M, Contreras G, Dell K, Fervenza F, Gibson K, Greenbaum L, Hernandez J, Hewitt S, Hingorani S, Hladunewich M, Hogan M, Hogan S, Kaskel J, Lieske J, Meyers K, Nachman P, Nast C, Neu A, Reich H, Sedor J, Sethna C, Trachtman H, Tuttle K, Zilleruelo G, and Kretzler M. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International advance online publication, 16 January 2013 doi:10.1038/ki.2012.428.</li>
<li>Akchurin O, Kaskel FJ. Late steroid resistance in childhood nephrotic syndrome: do we now know more that 40 years ago? Pediatr Nephrol. 2013 Aug;28(8):1157-60. PMID: 23708761</li>
<li> 17. Frederick Kaskel, Daniel Batlle, Srinivasan Beddhu, John Daugirdas, Harold Feldman, Maria Ferris, Lawrence Fine, Barry Freedman, Paul L Kimmel, Michael F Flessner, Robert A. Star, on behalf of the Kidney Research National Dialogue (KRND). Improving CKD Therapies and Care: A National Dialogue. CJASN (In Press).</li>
<li>18. Nephropathic Cystinosis: An International Consensus Document. NDT (in Press).</li>
</ol>
</div>
<p><strong> </strong></p>
<p>As Director of the Division of Pediatric Nephrology, Dr. Kaskel is involved in basic and clinical investigations into the mechanisms of the major kidney disorders in pediatrics. He is particularly interested in the physiology and pathophysiology of normal and abnormal development and function of the kidneys throughout the critical periods of growth and maturation extending into adolescence and young adulthood. He is actively involved in a clinical trial funded by the National Institutes of Health (NIH) to find the most efficacious therapy for focal segmental glomerulosclerosis, one of the major causes of progressive glomerular disease, while investigating the molecular etiologies for its expression. Another NIH-supported study involves chronic kidney disease in children and how it affects their growth and neurocognitive development, and the risk factors for cardiovascular disease and renal progression.</p><p>Dr. Kaskel is a past president of the American Society of Pediatric Nephrology, was Congress President of the International Pediatric Nephrology Association 15th Scientific Meeting, and has served as Chair for the Council of Nephrology and Urology of the National Kidney Foundation and the Kidney and Urology Foundation of America. He has also served on the Cardiovascular Renal Advisory Panel of the Food and Drug Administration (FDA) and as Associate Editor for the <em>Journal of the IPNA Pediatric Nephrology</em>. In addition, he has been named one of the Best Doctors in America and New York and as a Super Doctor by <em>New York Times</em> Magazine.</p>
Nicole A. Hayde
<p>Nicole Hayde, MD, MS, is a pediatric nephrologist at Children’s Hospital at Montefiore Einstein (CHAM), Medical Director, Pediatric Kidney Transplant Program, Associate Director, Pediatric Nephrology Fellowship Program and Associate Professor, Pediatrics at Montefiore-Einstein. Dr. Hayde’s clinical focus is pediatric renal transplantation, with a particular interest in the role of antibodies in allograft injury.</p><p>After earning her Doctor of Medicine from the University of the West Indies, Mona, Jamaica in 2003, Dr. Hayde completed her residency and chief residency in pediatrics at the University of Miami in 2009. She went on to complete her fellowship in pediatric nephrology at CHAM in 2012. During her fellowship, she was also enrolled in the clinical research training program at Einstein, earning her Master of Science in clinical research methods in 2012.</p><p>Dr. Hayde’s research focus is on the role of donor-specific antibodies in pediatric kidney transplantation and methods to decrease antibody mediated injury. Her findings have been published in several peer-reviewed journals, and have been shared through book chapters, posters and presentations. She is on the editorial board of Frontiers in Pediatrics and is a peer reviewer for several journals including Transplantation, Pediatric Transplantation and Human Immunology. She also serves as a research mentor for fellows interested in kidney transplant research.</p><p>Dr. Hayde is board certified in pediatrics and pediatric nephrology. She has several national roles including the associate councilor of region 9 of United Network of Organ Sharing (UNOS) and the executive committee of the pediatric community of practice of the American Society of Transplantation. She is also a member of several professional organizations including the ASPN and the American Society of Histocompatibility and Immunogenetics.</p>
Samuel V. Gorstein
<p>Samuel Gorstein, MD, is Director, Resident Education, Pediatric Intensive Care Unit (PICU) at the Children’s Hospital at Montefiore Einstein (CHAM) and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Gorstein’s clinical focus is on the care of critically ill infants, children and adolescents, focusing on conditions requiring intensive monitoring, life support and complex interventions, such as respiratory failure, sepsis, trauma and post-surgical recovery.
</p><p>After obtaining a Bachelor of Science in Biophysics from Brown University, Dr. Gorstein attended the University of Massachusetts Medical School, where he received his Doctor of Medicine in 2009. He then began his postgraduate training with an internship and residency in Pediatrics at Baystate Medical Center from 2009 to 2012. In 2015, he completed a fellowship in Pediatric Critical Care at Massachusetts General Hospital. </p><p>Dr. Gorstein oversees resident education in the PICU and has developed a didactic curriculum for residents rotating through the PICU at CHAM. His research aligns with his clinical expertise, and his work has been shared through peer-reviewed publications, invited presentations, abstracts, and poster presentations at professional meetings. </p><p>Dr. Gorstein is board-certified in Pediatrics and Pediatric Critical Care Medicine. He is a member of the American Academy of Pediatrics and the Society of Critical Care Medicine.
</p>
Beatrice Goilav
<p>Pediatric Nephrology, lupus nephritis</p>
Polycystic kidney disease; lupus nephritis; biomarkers of acute kidney injury
The role of microRNAs in the development of lupus nephritis and their role in the modulation of the expression of neutrophil gelatinase-associated lipocalin (NGAL) and as urinary biomarkers of disease activity
<p>Dr. Goilav is a pediatric nephrologist who is board certified in Pediatrics and Pediatric Nephrology. Her research interest is in lupus nephritis. She is currently doing translational research studying the role of very small interfering RNAs, called microRNAs, in the development and progression of lupus nephritis and their detection in human urine samples, as well as their role as biomarkers of disease activity.</p><p>Dr. Goilav graduated from the Faculty of Medicine, University of Basel, Switzerland, and did her internship and residency in pediatrics at Jacobi Medical Center. She completed her fellowship in pediatric nephrology at Mount Sinai School of Medicine. Dr. Goilav speaks <span>German, </span><span>Italian, </span><span>Spanish, </span><span>French, </span>Hebrew, and Romanian. </p><p><br /></p>